SAINT-GOBAIN-LIFE
15.6.2022 15:57:11 CEST | Business Wire | Press release
Saint-Gobain Life Sciences today announced the addition of their Suwa, Japan manufacturing facility for the production of C-Flex® TPE tubing for use in bioprocessing. The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005135/en/
“The Suwa site expansion further enhances our global manufacturing network, with a specific emphasis on supporting availability of our C-Flex® TPE tubing in Asia,” said Benjamin Le Quéré, Bioprocess Solutions business unit General Manager at Saint-Gobain Life Sciences. “With the completion of Suwa’s capability, we will have C-Flex® production capacity in five separate facilities in four countries. This is a unique capability in TPE tubing for bioprocessing and it supports our mission to provide security of supply.”
Site Location |
Operational Status |
Clearwater, FL USA |
Operational |
Charny, FRA |
Operational |
Largo, FL USA |
Operational |
Bangalore, IND |
Operational |
Suwa, JPN |
Planned Q4 2022 |
Hangzhou, CHN |
Planned Q1 2023 |
“We have been making substantial progress on improving C-Flex® service levels and lead-times through Q2 of this year,” said Le Quéré. “The Suwa, Japan production capacity being added in Q4 and the addition of Hangzhou capacity in early 2023 will further strengthen our ability to meet the needs of the bioprocess industry.”
The C-Flex® production expansion to the Saint-Gobain facility in Suwa, Japan is part of a multi-year manufacturing strategy, increasing Bioprocess Solutions business unit production capacity around the globe, creating redundant manufacturing capabilities across Europe, North America, and Asia to support increasing customer demand.
The Saint-Gobain Suwa facility has been in operation since 1992 and employs approximately 100 employees, providing production capability to multiple businesses within the Saint-Gobain Group.
About Saint-Gobain Life Sciences
Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical, and pharmaceutical customers around the world.
Saint-Gobain Life Sciences is part of Saint-Gobain Group, a worldwide leader in light and sustainable construction, which designs, manufactures, and distributes materials and services for the construction and industrial markets.
€44.2 billion in sales in 2021
166,000 employees, located in 75 countries
Committed to achieving Carbon Neutrality by 2050
For more details on Saint-Gobain, visit: http://www.saint-gobain.com and follow us on Twitter @saintgobain.
And visit: https://www.biopharm.saint-gobain.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience23.2.2026 15:13:00 CET | Press release
Express Access, Party Favors, and Private Room with Decorations and Ghirardelli Ice Cream Sundaes Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/ The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience “From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-fa
Xsolla Co-Sponsors Gamescom Dev Leadership Summit in Lisbon, Bringing Together Gaming Industry Leaders to Shape the Future of Game Development23.2.2026 15:00:00 CET | Press release
Platform Supporting 1,500+ Game Developers Across 200+ Geographies to Host Networking Dinner and Co-Moderate Strategic Roundtable at Premier European Gaming Executive Summit Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its co-sponsorship of the Gamescom Dev Leadership Summit Lisbon, taking place February 24-26 at SUD Lisboa in Portugal. The event brings together gaming industry executives, studio founders, and business leaders to explore opportunities and innovations shaping the future of game development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223253705/en/ Graphic: Xsolla As part of its sponsorship, Xsolla will host the summit's Wednesday evening networking dinner and co-moderate a strategic roundtable session focused on business models and sustainable growth in the gaming industry. "We're seeing incredible innovation from studios acro
CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform23.2.2026 15:00:00 CET | Press release
Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a real PCR-free DNA nanoarray technology. Separately, Swiss Rockets AG announced that it has entered into a definitive agreement to acquire 100% ownership of Complete Genomics. CoolMPS 600 enables cost-effective extended single-end sequencing to 600 bases (SE600) while maintaining high base accuracy. The system is designed to support advanced whole-genome sequencing (WGS) with improved mapping accuracy across complex genomic regions, including better detection of structural variants. It also enables full length transcriptomes and more infor
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom